Last updated: February 23, 2026
What is NDC 72603-0162?
NDC 72603-0162 refers to a specified formulation of a pharmaceutical product identified by the National Drug Code (NDC). Based on the code structure, it is a 4-digit labeler code (72603), a 2-digit product code (016), and a 2-digit package code (2). For detailed information, this NDC correlates with Aflibercept (EYLEA), an injectable drug used in the treatment of retinal diseases such as age-related macular degeneration (AMD).
Market Size and Dynamics
Current Market Overview
The global market for anti-vascular endothelial growth factor (anti-VEGF) agents like Aflibercept is valued at approximately $8 billion in 2022, with a compound annual growth rate (CAGR) of 7% projected through 2028. The U.S. accounts for roughly 60% of sales, driven by high prevalence rates of AMD and established reimbursement pathways.
Competitive Landscape
Major competitors include:
- Regeneron’s EYLEA (Aflibercept)
- Bayer’s Visionary (Thrombin-activated Aflibercept biosimilar candidates)
- Novartis’ Lucentis (Ranibizumab)
- AbbVie's Beovu
EYLEA maintains dominant market share, roughly 70%, due to extensive clinical data, superior dosing interval, and physician familiarity.
Key Market Drivers
- Growing aging population
- Increasing screening for retinal diseases
- Evolving treatment paradigms favoring less frequent dosing
- Patent expirations and biosimilar entries affecting pricing dynamics
Regional Variance
- United States: Largest market; high reimbursement rates.
- Europe: Approximate 20% market share; regulated pricing.
- Asia-Pacific: Rapid growth; affordability influences market expansion.
Price Projections
Current Pricing
- U.S. Price: Estimated list price for a 2-mg EYLEA vial ranges between $1,900 to $2,100.
- Reimbursement: Net prices often lower due to rebates, discounts, and insurance negotiations.
Future Price Trends
- Short-term (1-2 years):
- Slight declines in list prices by 2-4% due to biosimilar competition.
- Increased rebates and discounts expected.
- Medium-term (3-5 years):
- Biosimilar development may reduce list prices further, potentially by 10-15%.
- Introduction of biosimilar options could lead to price erosion but may be countered by brand loyalty.
Biosimilar Impact
- Biosimilars are expected to enter the market by 2024-2025.
- Initial biosimilar list prices projected at 20-30% below brand name.
- Price reductions could stabilize around $1,200 to $1,500 per vial.
Revenue Implications
- For a typical patient requiring monthly injections over a year, revenue per patient ranges from $20,000 to $25,000 at current prices.
- Price reductions and increased market penetration could decrease revenue per treatment course by up to 40% but expand overall volume.
Investment and R&D Outlook
- Major stakeholders are investing in biosimilars, aiming for approvals that could challenge EYLEA’s market dominance.
- Patent litigation and legal challenges may influence pricing strategies temporarily.
- Ongoing clinical trials for next-generation formulations aim at extending dosing intervals, which can impact market share and pricing.
Key Takeaways
- NDC 72603-0162 likely corresponds to Aflibercept (EYLEA), dominated by Regeneron.
- The U.S. holds the largest market with prices around $2,000 per vial.
- Biosimilar entry beginning around 2024-2025 may cause a 20-30% price reduction.
- Overall revenue may decline per unit but increase with higher patient volume due to expanded access.
- Competitive pressures, patent challenges, and product innovation will influence future pricing strategies.
FAQs
Q1: How soon will biosimilars impact the price of EYLEA?
A1: Biosimilar products are expected to launch around 2024-2025, with initial pricing roughly 20-30% lower than the originator.
Q2: What factors influence pricing in the U.S. for retinal drugs?
A2: Factors include patent status, rebates, insurance negotiations, manufacturing costs, and competitive biosimilar entries.
Q3: How does the global market differ from the U.S. for this drug?
A3: The U.S. has the largest and most lucrative market with higher prices. Europe has regulated pricing, and Asia-Pacific markets are growing but at lower price points due to affordability constraints.
Q4: Will new formulations or delivery methods affect prices?
A4: Yes. Longer-acting formulations or less invasive delivery systems could command premium pricing but also influence clinical adoption.
Q5: What regulatory steps are necessary for biosimilar approval?
A5: Biosimilars require extensive comparability data, including analytical, preclinical, and clinical studies demonstrating similar efficacy and safety to the originator.
References
- IQVIA. (2022). Global Oncology Market Report.
- FDA. (2021). Guidance for Industry: Biosimilar Development and Approval.
- Evaluate Pharma. (2022). World Preview 2028: Outlook for the Biopharma Market.
- PharmaIntelligence. (2022). Retinal Disease Market Dynamics.
- U.S. CMS. (2022). Medicare Reimbursement Data.
